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C-reactive protein (CRP) and other inﬂammatory biomarkers can indicate both the severity
and extent of atherosclerosis, reﬂecting the inﬂammatory nature of the disease process.1 Ath-
erogenesis begins with an inﬂammatory response to vascular injury with cells and mediators
initiating the healing response and later inducing growth of atherosclerotic plaques. In-
ﬂammation then increases plaque instability, promoting rupture, ﬁssuring, or erosion—the
pathogenetic milieu of thrombosis in atherothrombotic ischemic strokes.
Few studies have examined the predictive role of inﬂammatory markers with regard to the
eﬃcacy of the most common cardiovascular drugs such as statins, antihypertensive drugs, and
antiplatelet agents. Previous results from Justiﬁcation for the Use of Statins in Prevention: An
Intervention Trial Evaluating Rosuvastatin (JUPITER)2 reported that, among patients with
a high serum levels level of CRP, statin therapy resulted in a lower risk of cardiovascular events.
In the Physicians Health Study,3 baseline CRP levels inﬂuenced the magnitude of reduction in
the risk of myocardial infarction with aspirin therapy.
In this issue of Neurology®, Li et al.4 show the analysis of the relationship of high-sensitive CRP
(hsCRP) to the eﬃcacy of dual antiplatelet therapy in patients with and without intracranial
arterial stenosis in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebro-
vascular Events (CHANCE) trial. Among patients with minor stroke or high-risk TIA, they
found a clear relationship between serum levels of hsCRP and the eﬀectiveness of dual anti-
platelet therapy for preventing recurrent stroke in patients with intracranial arterial stenosis
even after correction for confounding factors. The authors observed that with dual antiplatelet
therapy (clopidogrel plus aspirin) there was reduced stroke recurrence, but only in patients with
low hsCRP serum levels. Moreover, patients with elevated hsCRP levels did not beneﬁt from
dual antiplatelet therapy, even after correction for use of antihypertensive agents and lipid-
lowering agents, during the 90-day follow-up period. They found similar results for the outcome
of composite vascular events. Patients without intracranial arterial stenosis did not demonstrate
an interaction between hsCRP and antiplatelet therapy for either recurrent stroke or the
combined vascular endpoint. Thus, the authors concluded that the protective role of dual
antiplatelet therapy is strictly linked to atherosclerosis localization and ongoing inﬂammation.
Atherosclerosis of precerebral and intracerebral arteries characterized by chronic vessel in-
ﬂammation is the main pathogenetic factor of atherosclerotic stroke. An acute cerebral athe-
rothrombotic event reﬂects a dramatic change from a chronic indolent inﬂammatory process to
a fulminate process with thrombosis on an active plaque. This transition begins with increased
leukocytosis within the atheroma and recruitment of additional leukocytes, followed by deg-
radation of the ﬁbrous cap, and ﬁnally plaque rupture and exposure of subendothelial tissue
factor to the hemostatic components of blood such as platelets.
Aspirin inﬂuences platelet function by acetylation of the platelet cyclooxygenase with irre-
versible inhibition of platelet-dependent thromboxane formation.5 Clopidogrel, a thienopyr-
idine and adenosine diphosphate receptor antagonist, inhibits platelet function through
irreversible binding to the G-protein-coupled P2Y12 receptor.6 Platelet activation caused by
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several factors, such as shear stress and inﬂammation, results
in resistance against inhibition of platelet function by aspirin
and other antiplatelet such as clopidogrel.
The results of this study provide food for thought that in-
ﬂammatory marker levels, as a surrogate for ongoing in-
ﬂammation, may inﬂuence cerebrovascular and vascular
endpoints, but only in persons with intracranial arterial ste-
nosis. The burden of intracerebral artery stenosis on the pa-
thology of atherosclerotic ischemic stroke, although reported,7,8
remains incompletely characterized. The study conducted by Li
et al. can shift our attention to patients with intracranial ath-
erosclerosis who demonstrate a clearer relationship between
inﬂammatory burden and eﬀectiveness of dual antiplatelet
therapy than those with carotid atherosclerosis.9
This interesting relationship could reﬂect a particularly de-
cisive role that local and systemic inﬂammation of plaques has
in those with intracranial arterial stenosis, determining the
complex local events that trigger the transition from chronic
stability to the acute event. More advanced methods, such as
MRI of plaque or FDG-PET used to evaluate inﬂammation
status of carotid plaque,10 may hold promise for assessing
intracerebral atherosclerotic disease, but this needs formal
investigation with characterization of inﬂammatory changes in
intracranial arterial plaques. The diﬃculty of ﬁnding in-
tracranial plaques to study has limited the investigation of
intracerebral plaque composition, the frequency of intra-
plaque inﬂammatory cells, and the more general concept of
plaque stability depending on the diﬀerent inﬂammation
grade. Nevertheless, important information emerges from this
study regarding the role that the inﬂammatory background
seems to play in the systemic platelet response and patho-
genesis of local plaque microevents involved in the presence
of activated platelets in acute ischemic stroke pathogenesis.
As indicated by the authors, this study has limitations. They
used magnetic resonance angiography as a noninvasive,
easily accessible technique rather than digital subtraction
angiography, the gold standard of diagnosis of intracranial
arterial stenosis. The venous blood samples were
collected after administration of the ﬁrst dosage of anti-
platelet drug.
This article provides an important addition to the literature,
oﬀering clariﬁcation on several details on diﬀerent therapeutic
roles of cardiovascular drugs such as antiplatelets or statins in
relation to atherosclerosis localization and inﬂammatory
background. These results suggest new tools to characterize
clinical and therapeutic phenotyping of patients at greater risk
of stroke. Finally, this study addresses a key question: Does
a relationship between inﬂammatory markers and antiplatelet
drug eﬀectiveness in persons with cerebrovascular athero-
sclerosis exist? This study oﬀers an intriguing answer: yes, but
only in intracranial vasculature.
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